This is the authors' abstract. We don't add key points for this paper.
Crohn's disease (CrD) is characterised by an ongoing inflammatory response in the gut, in the absence of an obvious trigger. The treatment of CrD in children, during relapse and remission, requires special consideration of growth and development. This review addresses the use of present medical management strategies, including enteral nutrition, corticosteroids, immunosuppression and anti-TNF-alpha therapies. Anti-inflammatory IL-11 and leukocyte adhesion inhibitors have shown only moderate clinical efficacy in adults. Emerging treatments directed against the inflammatory cascade under investigation include inhibitors of IL-6 and -12, IFN-gamma and MAPKs. Probiotics and colony stimulating factors aim to stimulate the innate immune system. Research data from clinical trials are reviewed and summarised in respect of their potential within paediatric practice.
Answers are grounded in this paper and cite their sources.
No takes yet. Share an insight, caveat, or question.
Bremner et al. (2007) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: